Re: Farmas USA
CTIC
$CTIC: Cell Therapeutics multi-kinase inhibitor CT-1578 demonstrates ability to prevent the onset of rheumatoid arthritis and potency in treating and reversing bone and cartilage damage in preclinical models (1.46)
Co announces that CT-1578's unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis, but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models, as reported in the Journal of Immunology. The authors concluded that CT-1578's selective inhibition of JAK2, FLT-3 and c-Fms, which are the three kinases that are critical to the pathogenesis of RA, is unprecedented in the current stable of kinase inhibitors. "The results demonstrate that CT-1578's unique kinase spectrum not only blocks the inflammatory response, but prevents the infiltration of macrophages and neutrophils into affected joints, while inhibiting antigen presenting dendritic cells and the autoimmune component of the disease. These attributes resulted in prevention of joint synovial hyperplasia and bone destruction, that was sufficiently impressive..."
http://www.briefing.com/Investor/PopupPages/ArticlePopup.aspx?ArticleId=IN20121015013200CTIC
